Drug intelligence / Profile preview

Corzea D3

Development stage: Unknown
Lead developer: Zealina Life Sciences
Modality: Small Molecules
Administration: Oral

Overview

Corzea D3 is a nutritional supplement developed and marketed by Zealina Life Sciences. It is a combination product containing 500 mg of elemental calcium, derived from coral grains (calcium carbonate), and 2000 IU of Vitamin D3 (cholecalciferol). Formulated as an oral tablet, it is primarily used to prevent and manage vitamin D deficiency, support the absorption of calcium and phosphorus, and maintain bone density and strength. It also plays a role in supporting healthy teeth, nerve conduction, and muscle contraction. The product is approved and commercially available in India.

Brand names: Corzea D3Corsea D3

Targets

CaSR (Extracellular calcium-sensing receptor)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Corzea D3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corzea D3.

Explore the full profile